- Innovation in pharma is of key importance. This is a priority for all who are looking for an effective health care system, Michał Byliniak, CEO of the Employers’ Union of Innovative Pharmaceutical Companies INFARMA, explained during the Economic Forum in Karpacz.
Challenges currently facing the health care system include the health debt after the Covid-19 pandemic, which translates into patients’ health deterioration due to long waiting lists for specialists’ consultations. Other factors include civilisation diseases and aging population.
Czytaj więcej
Firmy farmaceutyczne poszukują skuteczniejszych i szybszych dróg leczenia, przedłużania życia lub jego ratowania
Michał Byliniak explained how innovative therapies can help. - Many diseases that are treated with new-generation drugs become benign and the patients go through them in better shape. The recovery process is shortened. Patients reach a satisfactory standard of living much quicker, so that they are well enough to take up professional development or family activities.
He noted that in Poland, there is still a lot to be done within this area. - We are moving away from comparing ourselves with Western Europe, where the maturity of health care systems is at a completely different level. INFARMA carried out an analysis of the solutions implemented in the countries of the Visegrád Group. We also looked the European research and scientific societies’ recommendations. Although innovation in Poland is noticeable and decision-makers are aware of the value it brings, as a country we still have a long way to go.